Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New database aims to crack the code on three rare skin cancers

NCT ID NCT03210935

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is building a large French database of patients with three rare skin cancers: Merkel cell carcinoma, advanced basal cell carcinoma, and cutaneous adnexal carcinomas. Researchers will track up to 9,000 participants to learn how these cancers behave, what factors affect prognosis, and how different treatments impact outcomes. The goal is to gather real-world evidence to improve future care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide doctors with better information to predict how these rare skin cancers behave and which treatments work best.
What could go wrong
This is an observational study, not a treatment trial. It will not directly test a new drug or cure, and results may take years to influence patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 9,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2015

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma Exclusion Criteria: * Subjects without Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma * Patients refusal

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adnexal tumor of skin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

basal cell carcinoma cutaneous neuroendocrine carcinoma epidermal appendage tumor skin appendage carcinoma skin basal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adnexal tumor of skin Advanced basal cell carcinoma requiring systemic treatment Merkel cell carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    34 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Annecy Gennevois

    RECRUITING

    Annecy, France

  • CH Le Mans

    RECRUITING

    Le Mans, Le Mans, 72037, France

  • CHR d'Orleans

    RECRUITING

    Orléans, France

  • CHU Ambroise Paré

    RECRUITING

    Boulogne-Billancourt, France

  • CHU Amiens Picardie

    RECRUITING

    Amiens, France

  • CHU Angers

    RECRUITING

    Angers, France

  • CHU Avicenne

    RECRUITING

    Bobigny, France

  • CHU Besançon

    RECRUITING

    Besançon, France

  • CHU Bichat

    RECRUITING

    Paris, France

  • CHU Bocage

    RECRUITING

    Dijon, Dijon, 21079, France

  • CHU Cochin

    RECRUITING

    Paris, France

  • CHU Nantes - Place Alexis Ricordeau

    RECRUITING

    Nantes, France

  • CHU St Louis

    RECRUITING

    Paris, France

  • CHU de Bordeaux

    RECRUITING

    Pessac, France

  • CHU de Brest

    RECRUITING

    Brest, France

  • CHU de Caen

    RECRUITING

    Caen, France

  • CHU de Clermont Ferrand

    RECRUITING

    Clermont-Ferrand, France

  • CHU de Grenoble

    RECRUITING

    Grenoble, France

  • CHU de Limoges

    RECRUITING

    Limoges, France

  • CHU de Nancy

    RECRUITING

    Nancy, France

  • CHU de Nice

    RECRUITING

    Nice, France

  • CHU de Pointe à Pitre

    RECRUITING

    Pointe à Pitre, France

  • CHU de Poitiers

    RECRUITING

    Poitiers, France

  • CHU de Reims

    RECRUITING

    Reims, France

  • CHU de Rennes

    RECRUITING

    Rennes, France

  • CHU de Rouen

    RECRUITING

    Rouen, France

  • CHU de Strasbourg

    RECRUITING

    Strasbourg, France

  • CHU de Toulouse - Larrey

    RECRUITING

    Toulouse, France

  • CHU de Tours

    RECRUITING

    Tours, France

  • Centre Léon Bérard

    RECRUITING

    Lyon, France

  • Centre hospitalier Lyon Sud

    RECRUITING

    Pierre-Bénite, Pierre-benite, 69495, France

  • Hôpital La Timone

    RECRUITING

    Marseille, France

  • Hôpital St Eloi

    RECRUITING

    Montpellier, France

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.